[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Correction
April 25, 2012

Error in Financial Disclosure in: Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial

JAMA. 2012;307(16):1694. doi:10.1001/jama.2012.536

Error in Financial Disclosure. In the Original Contribution entitled “Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial,” published in the September 21, 2011, issue of JAMA (2011;306[11]:1224-1232), the financial disclosure for Dr March was incorrect. It should have read: “Dr March reported that he is a scientific advisor for Pfizer, Lilly, Bristol-Myers-Squib, and Shire Pharmaceuticals; receives research support from Pfizer, is a member of the data safety and monitoring boards for Otsuka and Lilly, is an equity holder in MedAvante; and receives royalties from MultiSystems for the Multidimensional Anxiety Scale for Children and for books from Guilford and from Oxford University Press.”

×